John Pribis
Oprichter bij Solu Therapeutics
Profiel
John Pribis is the founder of Solu Therapeutics, Inc. Prior to founding Solu Therapeutics, he worked as an Associate at Flagship Pioneering.
He received his undergraduate degree from Drexel University and his graduate degree from Baylor College of Medicine.
Actieve functies van John Pribis
| Bedrijven | Functie | Begin |
|---|---|---|
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Oprichter | - |
Eerdere bekende functies van John Pribis
| Bedrijven | Functie | Einde |
|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Analist | - |
Opleiding van John Pribis
| Baylor College of Medicine | Graduate Degree |
| Drexel University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Health Technology |